Efficacy of Vonoprazan for treatment functional dyspepsia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20201214004

Enrollment

Registered

2020-12-14

Start date

2020-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyspepsia&#44

Interventions

Omeprazole 20 mg once daily for 4 weeks assess SODA score and NDI score at baseline&#44

wk2&#44

and wk4,Vonoprazan 20 mg once daily for 4 weeks assess SODA score and NDI score at baseline&#44

and wk4

Active Comparator Drug,Experimental Drug

Omeprazole groups,Vonoprazan

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Functional dyspepsia (ROME IV criteria) 2.Informed consent form

Exclusion criteria

Exclusion criteria: 1. History of Helicobacter pylori infection 2. GI malignancy 3. Gastrectomy 4. HIV infection 5. Immunocompromised patients with on immunosuppression 6. Atazanavir, Rilpivirine, NSAIDs, Antiplatelet, Anticoagulant 7. Cirrhotic patients 8. Abnormal renal function (GFR < 30 ) 9. Allery to omeprazole or vonoprazan 10. Drug abuses 11. Pregnant and lactation 12. withdrawl from research

Design outcomes

Primary

Measure	Time frame
efficacy in treatment dyspepsia 4 weeks Severity of Dyspepsia Assessment score	—

Secondary

Measure	Time frame
quality of life 4 weeks Short form Nepean dyspepsia index,adverse events 4 weeks numbers of events	—

Countries

Thailand

Contacts

Public ContactNantaporn Srivantichapoom

Faculty of medicine Ramathibodi hospital Mahidol university

nantaporn076@gmail.com0892038372

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026